Zealand Pharma Toekomstige groei

Future criteriumcontroles 5/6

Zealand Pharma zal naar verwachting groeien in winst en omzet met respectievelijk 65.8% en 50.4% per jaar. De winst per aandeel zal naar verwachting groeien met 48.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -7.3% zijn.

Belangrijke informatie

65.8%

Groei van de winst

48.1%

Groei van de winst per aandeel

Biotechs winstgroei	26.7%
Inkomstengroei	50.4%
Toekomstig rendement op eigen vermogen	-7.3%
Dekking van analisten	Good
Laatst bijgewerkt	15 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

OTCPK:ZLDP.F - Toekomstschattingen van analisten en financiële gegevens uit het verleden (DKK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2,642	1,076	-22	-164	10
12/31/2025	1,785	353	2,219	1,758	11
12/31/2024	452	-700	-1,077	-1,023	10
9/30/2024	77	-1,053	-711	-691	N/A
6/30/2024	368	-712	-538	-508	N/A
3/31/2024	344	-739	-479	-453	N/A
12/31/2023	343	-704	-449	-426	N/A
9/30/2023	343	-760	-778	-758	N/A
6/30/2023	92	-986	-782	-771	N/A
3/31/2023	107	-1,064	-831	-822	N/A
12/31/2022	104	-966	-954	-942	N/A
9/30/2022	93	-855	-999	-978	N/A
6/30/2022	104	-845	-1,083	-1,060	N/A
3/31/2022	114	-608	-1,182	-1,161	N/A
12/31/2021	109	-755	-1,234	-1,212	N/A
9/30/2021	158	-925	-1,183	-1,181	N/A
6/30/2021	161	-1,012	-1,085	-1,071	N/A
3/31/2021	347	-909	-870	-844	N/A
12/31/2020	192	-669	-714	-689	N/A
9/30/2020	301	-660	-618	-580	N/A
6/30/2020	255	-545	-670	-632	N/A
3/31/2020	54	-624	-698	-671	N/A
12/31/2019	41	-572	-433	-409	N/A
9/30/2019	43	-508	-408	-391	N/A
6/30/2019	33	524	927	-346	N/A
3/31/2019	28	551	952	-320	N/A
12/31/2018	38	581	810	-461	N/A
9/30/2018	35	601	853	-417	N/A
6/30/2018	74	-361	N/A	-310	N/A
3/31/2018	68	-346	N/A	-320	N/A
12/31/2017	136	-274	N/A	-279	N/A
9/30/2017	306	-112	N/A	-64	N/A
6/30/2017	307	-100	N/A	-113	N/A
3/31/2017	306	-102	N/A	-52	N/A
12/31/2016	231	-157	N/A	41	N/A
9/30/2016	221	-138	N/A	-114	N/A
6/30/2016	189	-158	N/A	-128	N/A
3/31/2016	188	-139	N/A	-120	N/A
12/31/2015	188	-114	N/A	-225	N/A
9/30/2015	27	-246	N/A	-216	N/A
6/30/2015	78	-178	N/A	-149	N/A
3/31/2015	75	-147	N/A	-146	N/A
12/31/2014	154	-65	N/A	-42	N/A
9/30/2014	151	-47	N/A	-50	N/A
6/30/2014	95	-98	N/A	-100	N/A
3/31/2014	92	-97	N/A	-85	N/A
12/31/2013	7	-184	N/A	-170	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat ZLDP.F de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat ZLDP.F de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat ZLDP.F binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van ZLDP.F ( 50.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van ZLDP.F ( 50.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat ZLDP.F binnen 3 jaar verliesgevend zal zijn.

Zealand Pharma Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Recent updates

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q2, 2024 Results on Aug 15, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

Zealand Pharma Announces CEO Changes

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven